{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:43:17Z","timestamp":1788172997534,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T00:00:00Z","timestamp":1451520000000},"content-version":"vor","delay-in-days":578,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.seizure.2014.02.011","type":"journal-article","created":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T01:39:33Z","timestamp":1393637973000},"page":"429-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease)"],"prefix":"10.1016","volume":"23","author":[{"given":"Erling P.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2014.02.011_bib0005","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1185\/03007995.2012.694362","article-title":"Valproate-induced hyperammonemic encephalopathy: a brief review","volume":"28","author":"Lewis","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.seizure.2014.02.011_bib0010","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/088307389701200709","article-title":"Asymptomatic hyperammonemia in children treated with valproic acid","volume":"12","author":"Altunbsak","year":"1997","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2009.04.002","article-title":"The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status","volume":"86","author":"Hamed","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2014.02.011_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2013.08.008","article-title":"Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes","volume":"50","author":"Jadav","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpn.2012.10.011","article-title":"Do females with juvenile ceroid lipofuscinosis (Batten disease) have a severe disease course? The Danish experience","volume":"17","author":"Nielsen","year":"2013","journal-title":"Eur J Pediatr Neurol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0030","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1528-1157.2000.tb04608.x","article-title":"Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis","volume":"41","author":"Aberg","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.02.011_bib0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/chi.0b013e31802ed8b2","article-title":"Case report: valproic acid and risperidone treatment leading to development of hyperammonemia and mania","volume":"46","author":"Carlson","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.seizure.2014.02.011_bib0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/08830738050200022001","article-title":"Topiramate-valproate-induced hyperammonemic encephalopathy syndrome: case report","volume":"20","author":"Cheung","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0045","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eplepsyres.2012.04.001","article-title":"Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients","volume":"101","author":"Yamamoto","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2014.02.011_bib0050","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.yebeh.2011.05.006","article-title":"Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism","volume":"21","author":"Gomez-Iba\u00f1ez","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2014.02.011_bib0055","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.genhosppsych.2011.12.009","article-title":"Valproate-induced hyperammonemic encephalopathy: an update on risk factors, clinical correlates and management","volume":"34","author":"Chopra","year":"2012","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.seizure.2014.02.011_bib0060","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/YIC.0b013e3281c61b28","article-title":"Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting","volume":"22","author":"Dealberto","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0065","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0269881109102635","article-title":"Clinical alertness to valproic acid-induced hyperammonemia\u2014two case reports","volume":"24","author":"Shan","year":"2010","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.jcp.0000138768.61600.ad","article-title":"Valproic acid-induced hyperammonemia","volume":"24","author":"McCall","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0075","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/02699050903302344","article-title":"Valproic acid-induced encephalopathy in very long course treated patients","volume":"23","author":"Rousseau","year":"2009","journal-title":"Brain Inj"},{"key":"10.1016\/j.seizure.2014.02.011_bib0080","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.pnpbp.2010.02.017","article-title":"Valproate-induced hyperammonemia in mental retardation: a case report and review of the literature","volume":"34","author":"Khoo","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.seizure.2014.02.011_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/802121","article-title":"Valproic acid-induced hyperammonemia in the elderly: a review of the literature","volume":"2009","author":"Mittal","year":"2009","journal-title":"Case Rep Med"},{"key":"10.1016\/j.seizure.2014.02.011_bib0090","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2990.2008.00984.x","article-title":"Altered arginine metabolism in the central nervous system (CNS) of the Cln3\u2212\/\u2212 mouse model of juvenile Batten disease","volume":"35","author":"Chan","year":"2009","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.seizure.2006.05.007","article-title":"Valproic acid induced encephalopathy\u201419 new cases in Germany from 1994 to 2003\u2014a side effect associated to VPA-therapy not only in young children","volume":"15","author":"Gerstner","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2014.02.011_bib0100","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.yebeh.2007.02.013","article-title":"Different clinical manifestations of hyperammonemic encephalopathy","volume":"10","author":"Gomceli","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2014.02.011_bib0105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.yebeh.2007.06.015","article-title":"The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist?","volume":"11","author":"Chicharro","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2014.02.011_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/epi.12125","article-title":"Risk factors for hyperammonemia in pediatric patients with epilepsy","volume":"54","author":"Yamamoto","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.02.011_bib0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s005990050060","article-title":"Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs","volume":"29","author":"Verrotti","year":"1999","journal-title":"Int J Clin Lab Res"},{"key":"10.1016\/j.seizure.2014.02.011_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00655.x","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"114","author":"Segura-Bruna","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2014.02.011_bib0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1875-9572(09)60010-3","article-title":"Valproate-induced hyperammonemic encephalopathy","volume":"49","author":"Chou","year":"2008","journal-title":"Pediatr Neonatol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.9.2.285","article-title":"Oral valproic acid for epilepsy \u2013 long-term experience","volume":"9","author":"Gerstner","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seizure.2014.02.011_bib0135","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1345\/aph.19242","article-title":"The role of carnintine supplementation during valproic acid therapy","volume":"34","author":"Raskind","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.seizure.2014.02.011_bib0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2146\/ajhp110049","article-title":"Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy","volume":"69","author":"Mock","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.seizure.2014.02.011_bib0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/15622975.2010.489619","article-title":"Clinical correlates of low serum carnitine levels in hospitalized psychiatric patients","volume":"12","author":"Cuturic","year":"2011","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.seizure.2014.02.011_bib0150","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1528-1157.1998.tb01315.x","article-title":"l-Carnitine supplementation in childhood epilepsy: current perspectives","volume":"39","author":"De Vivo","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.02.011_bib0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15563650902752376","article-title":"Carnitine in the treatment of valproic acid-induced toxicity","volume":"47","author":"Lheureux","year":"2009","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0160","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4088\/JCP.v66n0502","article-title":"Carnitine levels in valproic acid-treated psychiatric patients: a cross-sectional study","volume":"66","author":"Moreno","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.seizure.2014.02.011_bib0165","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0925-4439(96)00054-3","article-title":"Decreased plasma carnitine and trimethyl-l-lysine levels associated with lysosomal accumulation of a trimethyl-l-lysine containing protein in Batten disease","volume":"1317","author":"Katz","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.seizure.2014.02.011_bib0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/ejpn.2000.0453","article-title":"Assessment of dietary therapies in a canine model of Batten disease","volume":"5","author":"Siakotos","year":"2001","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/(SICI)1097-4547(19971001)50:1<123::AID-JNR13>3.0.CO;2-C","article-title":"Dietary carnitine supplements slow disease progression in a putative mouse model for hereditary ceroid-lipofuscinosis","volume":"50","author":"Katz","year":"1997","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.seizure.2014.02.011_bib0180","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1089\/cap.2010.2052","article-title":"Bipolar disorder and valproate-induced hyperammonemic encephalopathy in an adolescent with diabetes","volume":"20","author":"Young","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3122\/jabfm.2007.05.070062","article-title":"Valproate-associated hyperammonemic encephalopathy","volume":"20","author":"Wadzinski","year":"2007","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.seizure.2014.02.011_bib0190","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1176\/appi.psy.49.1.82","article-title":"Severe acute hyperammonemia after brief exposure to valproate","volume":"49","author":"Eubanks","year":"2008","journal-title":"Psychosomatics"},{"key":"10.1016\/j.seizure.2014.02.011_bib0195","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1345\/aph.1G167","article-title":"Acute hyperammonemic coma with chronic valproic acid therapy","volume":"39","author":"Cuturic","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.seizure.2014.02.011_bib0200","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/WNF.0b013e3181ac3615","article-title":"Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate","volume":"32","author":"Deutsch","year":"2009","journal-title":"Clin Neuropharm"},{"key":"10.1016\/j.seizure.2014.02.011_bib0205","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0404.2006.00793.x","article-title":"Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy","volume":"116","author":"Velio\u011flu","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2014.02.011_bib0210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00019442-200207000-00014","article-title":"Brief report: valproate-induced hyperammonemia as a cause of altered mental status","volume":"10","author":"Feil","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.seizure.2014.02.011_bib0215","doi-asserted-by":"crossref","first-page":"84.e3","DOI":"10.1016\/j.genhosppsych.2010.10.004","article-title":"The real mechanism of VPA-induced hyperammonemia remains unknown","volume":"33","author":"Hung","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.seizure.2014.02.011_bib0220","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1001\/archneur.63.8.1202","article-title":"Hippocampal involvement in valproate-induced acute hyperammonemic encephalopathy","volume":"63","author":"Soares-Fernandes","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0225","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1528-1157.2002.42201.x","article-title":"Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy","volume":"43","author":"Ziyeh","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2014.02.011_bib0230","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.pnpbp.2008.06.006","article-title":"Lamotrigine might potentiate valproic acid-induced hyperammonemic encephalopathy","volume":"32","author":"Fan","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.seizure.2014.02.011_bib0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1600-0404.2003.00227.x","article-title":"Case report. Hyperammonemic encephalopathy induced by a combination of valproate and pivmecillinam","volume":"109","author":"Lokrantz","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2014.02.011_bib0240","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/JCP.0b013e31817275b6","article-title":"A case of hyperammonemic encephalopathy after 11 years of valproate therapy","volume":"28","author":"Stewart","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.seizure.2014.02.011_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/969505","article-title":"A case of valproate induced hyperammonemic encephalopathy","volume":"2011","author":"Tarafdar","year":"2011","journal-title":"Case Rep Med"},{"key":"10.1016\/j.seizure.2014.02.011_bib0250","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/JCP.0b013e31822cd2a0","article-title":"Carnitine supplementation for valproate-related hyperammonemia to maintain therapeutic valproate level","volume":"31","author":"Sonik","year":"2011","journal-title":"J Clin Psychopharmacol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131114000624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131114000624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:43:25Z","timestamp":1761011005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131114000624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1059131114000624"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2014.02.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease)","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2014.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}